Table 4. Comparing the impact of no-calls when an unknown mutation is detected (process used in 20) versus that of Mykrobe.
| Global dataset | ||||
|---|---|---|---|---|
| Tool | Drug | TN | TP | FN |
| Mykrobe | Rifampicin | 2990 | 2634 | 136 |
| NEJM-2018 | Rifampicin | 2833 | 2614 | 72 |
| Mykrobe | Isoniazid | 2704 | 2781 | 187 |
| NEJM-2018 | Isoniazid | 2564 | 2747 | 86 |
| Mykrobe | Ethambutol | 3484 | 1381 | 187 |
| NEJM-2018 | Ethambutol | 3149 | 1339 | 82 |
| Mykrobe | Pyrazinamide | 2437 | 750 | 264 |
| NEJM-2018 | Pyrazinamide | 2176 | 732 | 90 |
| Prospective dataset | ||||
| Mykrobe | Rifampicin | 4143 | 133 | 0 |
| NEJM-2018 | Rifampicin | 3928 | 124 | 0 |
| Mykrobe | Isoniazid | 3931 | 312 | 17 |
| NEJM-2018 | Isoniazid | 3747 | 311 | 8 |
| Mykrobe | Ethambutol | 4170 | 71 | 49 |
| NEJM-2018 | Ethambutol | 3684 | 71 | 47 |
| Mykrobe | Pyrazinamide | 4048 | 102 | 23 |
| NEJM-2018 | Pyrazinamide | 3972 | 109 | 6 |